Benzinga · Aug 14, 2026
JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25
JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.
BB
NASDAQ · BBOT
BridgeBio Oncology Therapeutics Inc.
Healthcare · Biotechnology
$9.08
Up+$0.00 (+0.00%)
Updated Aug 22, 2026, 1:44 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.03B
- P/E ratio
- -2.62
- Dividend yield
- 0.00%
- 52-week range
- $7.00 – $14.87
- Volume
- 171.57K
- Avg. volume
- 237.22K
Price performance
BBOT price history
1M range · 21 trading sessions · Daily adjusted prices
BBOT closed at $9.08 after 21 trading sessions, up 2.95% for the selected period.
- Last close
- $9.08
- Period change
- +2.95%
- Period low
- $8.09
- Period high
- $9.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $9.19 | $9.4351 | $9.03 | $9.08 | 171.57K |
| Aug 20, 2026 | $9.55 | $9.78 | $9.08 | $9.08 | 203.26K |
| Aug 19, 2026 | $9.16 | $9.72 | $9.14 | $9.60 | 414.32K |
| Aug 18, 2026 | $9.02 | $9.125 | $8.82 | $8.95 | 446.87K |
| Aug 17, 2026 | $8.90 | $9.3999 | $8.90 | $9.04 | 249.91K |
| Aug 14, 2026 | $9.22 | $9.49 | $8.80 | $9.06 | 227.48K |
| Aug 13, 2026 | $9.48 | $9.61 | $9.20 | $9.23 | 303.83K |
| Aug 12, 2026 | $9.07 | $9.46 | $9.00 | $9.42 | 150.52K |
| Aug 11, 2026 | $9.33 | $9.44 | $9.095 | $9.20 | 202.03K |
| Aug 10, 2026 | $9.30 | $9.62 | $9.24 | $9.28 | 208.92K |
| Aug 7, 2026 | $8.91 | $9.42 | $8.8901 | $9.33 | 219.41K |
| Aug 6, 2026 | $8.98 | $9.31 | $8.75 | $8.78 | 186.96K |
| Aug 5, 2026 | $8.83 | $9.02 | $8.76 | $8.96 | 147.4K |
| Aug 4, 2026 | $8.27 | $8.87 | $8.225 | $8.87 | 507.09K |
| Aug 3, 2026 | $8.14 | $8.47 | $8.0001 | $8.25 | 210.12K |
| Jul 31, 2026 | $8.50 | $8.59 | $8.01 | $8.09 | 368.25K |
| Jul 30, 2026 | $8.27 | $8.645 | $8.10 | $8.50 | 293.44K |
| Jul 29, 2026 | $8.64 | $8.72 | $8.095 | $8.235 | 386.77K |
| Jul 28, 2026 | $8.77 | $8.85 | $8.46 | $8.59 | 129.18K |
| Jul 27, 2026 | $9.00 | $9.26 | $8.72 | $8.75 | 240.89K |
| Jul 24, 2026 | $8.75 | $8.95 | $8.41 | $8.82 | 186.15K |
Latest BBOT news
The latest Smart Investors Daily articles mentioning BBOT.
Stock researchCompany · Overview
BBOT research
Overview
Company profile and research snapshot.
Company profile
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.20
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | JP Morgan | Overweight | — |
| Jul 8, 2026 | JP Morgan | Overweight | — |
| May 11, 2026 | Canaccord Genuity | Buy | — |
| Mar 6, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 11, 2026 | Stifel | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 11, 2026
BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(705.20) per share which missed the analyst consensus estimate of $(0.57) by 123619.3 percent. This is a 24.49 percent decrease over losses of $(566.46) per
SeekingAlpha · Jul 13, 2026
BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment
BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage. Click for more on BBOT stock prospects.
Benzinga · Jul 8, 2026
JP Morgan Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $27
JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Overweight rating and announces Price Target of $27.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
